TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00201708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (AC)
Description: 600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (AC)
Description: 600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Study: NCT02819427

Intervention type: DEVICE
Intervention: Near Infra Red Spectroscopy (NIRS)

Intervention type: DEVICE
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
Study: NCT05602792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with advanced solid tumors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with sarcoma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with breast cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with esophagus cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with lung cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
Study: NCT01749111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM B Calcineurin inhibitor and methotrexate
Description: Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
Study: NCT03798782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ross procedure
Description: The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aortic valve replacement
Description: The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
Study: NCT03199118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF +SCTG
Description: the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF +SCTG
Description: the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
Study: NCT04958642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrabetadex
Description: Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
Study: NCT02182947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
Study: NCT03582943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC
Description: See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
Study: NCT03290430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
Study: NCT00453375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT-3021
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BHT-Placebo
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Study: NCT02659501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
Study: NCT01055990

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood fix
Description: The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
Study: NCT04805268

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: 18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
Study: NCT03202342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
Study: NCT02236988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Immediate Release
Description: 30 mg immediate release tablets
Study: NCT03202342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
Study: NCT02038153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT02343393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Study: NCT01101035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol tablets
Study: NCT01867749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT-G)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with Depression (CWD)
Study: NCT00555880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Description: one dose, 10-30mg, given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03584165

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.
Study: NCT05083429

Intervention type: DRUG
Intervention: Salmeterol
Description: Salmeterol inhaler dispensing claim is used as the reference

Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium dispensing claim is used as the reference
Study: NCT04551118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) -active
Description: Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)-active
Description: Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation (TES)-sham
Description: Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
Study: NCT00997919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: single IV dose
Study: NCT02430090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: this used in intratechal area and for spinal anesthesia in ceserean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: this used in intratechal area and for spinal anesthesia in ceserean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: this used in intratechal area and for spinal anesthesia in ceserean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: this used in intratechal area and for spinal anesthesia in ceserean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study: NCT02750852

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty, blood loss analysis
Description: Data analysis about blood loss in total hip replacement

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty, blood loss analysis
Description: Data analysis about blood loss in total hip replacement
Study: NCT02638324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal nervous denervation
Description: The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal nervous denervation
Description: The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
Study: NCT04593108

Intervention type: DEVICE
Intervention: Letrozole misoprostol
Description: Letrozole give pretreatment of abortion by misoprostol

Intervention type: DRUG
Intervention: Misoprostol, placebo
Description: Give placebo pretreatment of abortion by misoprostol
Study: NCT00799266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study: NCT04491968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.

Intervention type: OTHER
Group type: OTHER
Intervention: Methadone Treatment as Usual
Description: In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
Study: NCT02535325

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-D conformal RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV